Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients With Advanced Basal Cell Carcinoma

NCT03897036 is registered in ClinicalTrials.gov with Senhwa Biosciences, Inc. as lead sponsor.

NCT NCT03897036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03897036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients With Advanced Basal Cell Carcinoma
Lead sponsor
Senhwa Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 16, 2019
Completion date
January 25, 2024
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, basal cell